AXL and hepatocellular carcinoma: About 57% of PRAME-negative HCC samples lacked Axl, while 54% of PRAME-positive patients were Axl-positive as well (Figure 6G), which exhibited a more advanced tumor stage (Figure 6H) and a higher incidence of vascular invasion and recurrence (Figure 6I).